Multimodal Longitudinal and Predictive Modelling to Understand Eating Disorder Development

CompletedOBSERVATIONAL
Enrollment

23

Participants

Timeline

Start Date

November 15, 2023

Primary Completion Date

August 12, 2024

Study Completion Date

August 12, 2024

Conditions
Binge-Eating DisorderAnorexia NervosaBulimia Nervosa
Interventions
OTHER

MRI scans

"Neuroimaging data will be collected with magnetic resonance imaging (MRI).~Structural neuroimaging will include T1 and T2-weighted scans, and diffusion tensor imaging (DTI).~Functional neuroimaging will include scans under the stop-signal task, monetary incentive delay task, and emotional faces task, and resting state."

OTHER

Psychological measures

"Cognitive performance assessed by Wechsler Adult Intelligence Scale 4th Edition.~Personalities assessed by NEO Five-Factor Inventory (NEO-FFI), Substance Use Risk Profile Scale (SURPS), and Temperament and Character Inventory (TCI).~Other psychological assessments include Interpersonal Reactivity Index, Perceived Stress Scale, Kirby Monetary Choice Questionnaire, Passive Avoidance Learning Paradigm, and Stimulus-response compatibility."

OTHER

Life experiences

Self-report questionnaires on experiences of bullying and trauma.

BIOLOGICAL

Blood and urine samples

Blood and urine samples will be collected but will not undergo analysis in this study. Instead, these samples will be stored in a biobank for potential analysis in future research.

OTHER

Mental health symptoms

"Symptoms of depression measured by the Patient Health Questionnaire -8.~Symptoms of generalised anxiety, obsessives compulsive disorder, attention deficit hyperactivity disorder, social phobia, specific phobia, agoraphobia, post-traumatic stress disorder, measured by the Development and Well-Being Assessment (DAWBA).~Harmful drinking measured by the Alcohol use disorders identification test.~Drug use measured by the European School Survey Project on Alcohol and Other Drugs (ESPAD).~Suicide risk measured by the the Mini International Neuropsychiatric Interview."

Trial Locations (1)

SE5 8AF

Institute of Psychiatry, Psychology & Neuroscience, King's College London, London

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Delosis Limited

UNKNOWN

collaborator

NeuroSpin

UNKNOWN

lead

King's College London

OTHER